Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.75 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.73 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.73 |
| ▸ | FLT1 | P17948 | 1/20 | 0.73 |
| ▸ | FLT4 | P35916 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185108 | 0.93 | TGFBR1 (0.71) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL3179212 | 0.91 | TGFBR1 (0.71) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL1646966 | 0.90 | TGFBR1 (0.62) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL1648625 | 0.90 | TGFBR1 (0.72) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL4876173 | 0.90 | TGFBR1 (0.78) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL3174154 | 0.90 | TGFBR1 (0.71) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL3174009 | 0.89 | TGFBR1 (0.60) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL3176239 | 0.89 | TGFBR1 (0.75) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL4872136 | 0.89 | TGFBR1 (0.76) | TGFBR1MAPK14KDRPRKD1PDGFRA | |
| SCHEMBL1647183 | 0.89 | TGFBR1 (0.75) | TGFBR1MAPK14KDRPRKD1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410146-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-02 | — | — | US | claimed |
| US-20100022535-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors | SK CHEMICALS CO., LTD. (KR) | 2010-01-28 | — | — | US | claimed |
| WO-2009150547-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD (KR) | 2009-12-17 | — | — | WO | claimed |
| US-8410146-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-02 | — | — | US | disclosed |
| US-8410146-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-02 | — | — | US | disclosed |
| US-8410146-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | SK CHEMICALS CO., LTD. (KR) | 2013-04-02 | — | — | US | disclosed |
| EP-2303860-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2011-04-06 | — | — | EP | disclosed |
| US-20100022535-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors | SK CHEMICALS CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022535-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors | SK CHEMICALS CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| US-20100022535-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors | SK CHEMICALS CO., LTD. (KR) | 2010-01-28 | — | — | US | disclosed |
| WO-2009150547-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD (KR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150547-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK4 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD (KR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022535-A1 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors | ALK, ABL1, ERBB4 | TGFBR1 236/4885MAPK14 434/4885KDR 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.